If you are still having problems viewing this message, please click here for additional help.

Nature Reviews Drug Discovery

Advertisement
CRISPR Gene-Edited Cell Libraries: Rapid validation of research
 
Dr. Daniella Steel discusses how you can quickly validate your research saving precious time and resources with Horizon's CRISPR Gene-Edited Cell Line Libraries 

Read More
TABLE OF CONTENTS

June 2018 Volume 17, Issue 6

Comment
News and Analysis
Research Highlights
Reviews
 
Advertisement
nature.com webcasts

Nature Research
Custom presents a webcast on: Saving an Enzymatic HTS Assay with Sound
 
Date: Wednesday, June 13, 2018
 
Labcyte and Servier will present a recent experiment about Echo technology. Learn about the solutions for a robust enzymatic HTS assay and absorption issue.
 
This webcast has been produced on behalf of the sponsor who retains sole responsibility for content
 
 
Sponsored by: Labcyte 

 
Advertisement

BIOPHARMA DEALMAKERS
BIOPHARMA DEALMAKERSCompany Profiles and Partnering Opportunities

 
Advertisement
nature.com webcasts

Nature Research Custom Media presents a webcast on: Ultra-Sensitive Immunoassays: Beyond Biomarkers and into PK and Immunogenicity

Date: Thursday, June 21, 2018

Dr. Daniel Sikkema, Vice President of Quanterix will present the latest advances in biomarker testing and how to solve drug tolerance and characterization issues for immunogenicity.

This webcast has been produced on behalf of the sponsor who retains sole responsibility for content 

Register for FREE
 
Sponsored by: 
Quanterix
 
 

Comment

 

Accelerated approval of medicines: fit for purpose?    pp379 - 380
Alasdair Breckenridge & Lawrence Liberti
doi:10.1038/nrd.2017.245
The uptake of a new medicine represents a balance between benefit-risk assessment and value considerations. In the case of products approved via accelerated pathways, the increased uncertainty adds to the challenge. Here, we suggest solutions so that regulators, companies, payers and patients can align around management of the uncertainties and expectations.

News and Analysis

 

Sepsis researchers set sights on immunotherapeutic strategies    pp381 - 383
Asher Mullard
doi:10.1038/nrd.2018.87
Two immune-boosting strategies have independently indicated promise in sepsis clinical trials, after years of failures with anti-inflammatories in this same space. Will it be enough to take sepsis drug development out of 'critical condition'?

When drugs unintentionally affect gut bugs    pp383 - 384
Cassandra Willyard
doi:10.1038/nrd.2018.88
Many drugs unexpectedly influence the human gut microbiome, showed a recent study, prompting questions about toxicity assays, clinical implications and repurposing opportunities.

News in Brief

BACE failures lower AD expectations, again    p385
Asher Mullard
doi:10.1038/nrd.2018.94

On the origin of transformative drugs    p385
Asher Mullard
doi:10.1038/nrd.2018.95

FDA approves first-in-class SYK inhibitor    p385
Asher Mullard
doi:10.1038/nrd.2018.96

An Audience With

Norbert Bischofberger    pp386 - 387
doi:10.1038/nrd.2018.82
Norbert Bischofberger, former CSO of Gilead, discusses antiviral opportunities, Gilead's pivot to oncology and the need for a societal discussion of drug costs.

From the analyst's couch

What drives site performance in clinical trials?    pp389 - 390
Brendan Smith, Linda Martin, Scott Martin, Maria Denslow, Melissa Hutchens, Conrad Hawkins, Valery Panier & Michael S. Ringel
doi:10.1038/nrd.2018.51
This article highlights results from a comprehensive study of the performance of clinical trial sites, which could help companies understand the underlying drivers of success.

Advertisement
nature.com webcasts

Nature Research Custom presents a webcast on: Multicolour Digital PCR for ctDNA detection in breast cancer

Date: 12 June 2018

Dr. Isaac Garcia-Murillas from ICR will address the technical challenges for clinical utility of liquid biopsy and ctDNA as a biomarker in breast cancer.

This webcast has been produced on behalf of the sponsor who retains sole responsibility for content 

Register for FREE 

Sponsored by: Stilla Technologies 
 

Research Highlights

 

Neurodegenerative disorders: Rescuing mitochondrial motility    p391
Sarah Crunkhorn
doi:10.1038/nrd.2018.76

Neuroscience: Reconnecting the brain after injury    p392
M. Teresa Villanueva
doi:10.1038/nrd.2018.83

Cancer: Personalized cancer vaccines hit the spot    p393
Megan Cully
doi:10.1038/nrd.2018.85

In Brief

Cancer: Preventing metastatic relapse    p394
Sarah Crunkhorn
doi:10.1038/nrd.2018.78

Autoimmune disease: Targeting glucose transport in psoriasis    p394
Sarah Crunkhorn
doi:10.1038/nrd.2018.79

Liver disease: Reducing cancer risk    p394
Sarah Crunkhorn
doi:10.1038/nrd.2018.80

Cancer: Restoring p53 activity    p394
Sarah Crunkhorn
doi:10.1038/nrd.2018.81

Antibacterial drugs: Disrupting MRSA 'persisters'    p394
Conor A. Bradley
doi:10.1038/nrd.2018.84

Drug Discovery
JOBS of the week
Associate Director, Early Target Discovery
Takeda
Postdoctoral Scientist Postdoctoral Scientist
Boehringer Ingelheim
Multiple Faculty Positions at ShanghaiTech University
ShanghaiTech University
Nanotechnologies for Precision Medicine at CNR-NANOTEC
CNR Institute of Nanotechnology
More Science jobs from
Drug Discovery
EVENT
Drug Discovery 2018
09.10.18
London, UK
More science events from
Advertisement
nature.com webcasts

Nature Research Custom presents a webcast on: Structural Tools In Your MS Tool Box

Date: Wednesday, June 27, 2018

Dr. David Schriemer will provide some insights on how data from electron microscopy, H/D exchange and crosslinking mass spectrometry can be used together to solve complex structure-function problems.

This webcast has been produced on behalf of the sponsor who retains sole responsibility for content 

Register for FREE 

Sponsored by: Thermo Fisher Scientific 
 

Reviews

 

Interleukin-6: designing specific therapeutics for a complex cytokine    pp395 - 412
Christoph Garbers, Sylvia Heink, Thomas Korn & Stefan Rose-John
doi:10.1038/nrd.2018.45
Dysregulation of IL-6 signalling is associated with inflammatory and lymphoproliferative disorders, and several classes of therapeutics have been developed that target components of the IL-6 signalling pathway. This Review describes the progress made in recent years in inhibiting IL-6-signalling and analyses the advantages and disadvantages of these approaches.

Post-exposure treatments for Ebola and Marburg virus infections    pp413 - 434
Robert W. Cross, Chad E. Mire, Heinz Feldmann & Thomas W. Geisbert
doi:10.1038/nrd.2017.251
Efforts towards developing post-exposure therapies for infections with filoviruses, particularly Ebola and Marburg viruses, increased substantially during the Ebola virus outbreak of 2013-2016. Geisbert and colleagues review the progress made on this front and discuss the challenges and opportunities for developing post-exposure therapies in the future.

RNA-modifying proteins as anticancer drug targets    pp435 - 453
P. Ann Boriack-Sjodin, Scott Ribich & Robert A. Copeland
doi:10.1038/nrd.2018.71
Covalent modifications of RNA — mediated by RNA-modifying proteins (RMPs) — affect RNA stability and translation to proteins, and some of these RMPs have been implicated in cancer. Here, Copeland and colleagues review the current understanding of RNA modifications with a focus on mRNA methylation and assess the potential of RMPs as novel anticancer targets.

Advertisement
Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature